PureTech's latest spinoff Celea Therapeutics was created to progress the former's lead respiratory IPF programme, ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

PureTech Health has launched a subsidiary company – Celea Therapeutics – with the task of taking an experimental drug for ...

Senores Pharmaceuticals acquires two ANDAs from Teva Pharmaceuticals USA Inc., expanding its US market presence.

Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has ...

Corcept Therapeutics’ second quarter was marked by continued sales growth in its core endocrinology franchise, with ...

Teva Pharmaceuticals has received US FDA approval for AJOVY (fremanezumab-vfrm) as a preventive treatment for episodic migraine in children and adolescents aged 6–17 who weigh at least 45 kilograms.

Half Year Results/Half Year ReportFormycon confirms full-year guidance following business development in line with plan – working capital raised 13.08.2025 / 06:30 CET/CESTThe issuer is solely ...

Senores Pharmaceuticals rose 2.16% to Rs 687.75 after its US arm signed a deal to acquire two USFDA-approved ANDAs from Teva Pharmaceuticals USA, targeting a market size of up to $120 million.

Teva Pharmaceutical Industries (NYSE:TEVA) shares continued gains for seven straight sessions, as the stock closed 1% higher ...

The FDA has approved Ajovy for migraine prevention in children and teens, marking the first time a medication in its class is cleared for pediatric use.